405 related articles for article (PubMed ID: 24013409)
1. Physiological roles and potential therapeutic applications of the P2X7 receptor in inflammation and pain.
Alves LA; Bezerra RJ; Faria RX; Ferreira LG; da Silva Frutuoso V
Molecules; 2013 Sep; 18(9):10953-72. PubMed ID: 24013409
[TBL] [Abstract][Full Text] [Related]
2. P2X7 receptors: channels, pores and more.
Volonté C; Apolloni S; Skaper SD; Burnstock G
CNS Neurol Disord Drug Targets; 2012 Sep; 11(6):705-21. PubMed ID: 22963440
[TBL] [Abstract][Full Text] [Related]
3. P2X7 receptor antagonism prevents IL-1β release from salivary epithelial cells and reduces inflammation in a mouse model of autoimmune exocrinopathy.
Khalafalla MG; Woods LT; Camden JM; Khan AA; Limesand KH; Petris MJ; Erb L; Weisman GA
J Biol Chem; 2017 Oct; 292(40):16626-16637. PubMed ID: 28798231
[TBL] [Abstract][Full Text] [Related]
4. P2X7 receptor antagonists: a patent review (2010-2015).
Park JH; Kim YC
Expert Opin Ther Pat; 2017 Mar; 27(3):257-267. PubMed ID: 27724045
[TBL] [Abstract][Full Text] [Related]
5. Purinergic P2X7 Receptor: A Cation Channel Sensitive to Tumor Microenvironment.
Scarpellino G; Genova T; Munaron L
Recent Pat Anticancer Drug Discov; 2019; 14(1):32-38. PubMed ID: 30652649
[TBL] [Abstract][Full Text] [Related]
6. P2X7 receptor-stimulation causes fever via PGE2 and IL-1β release.
Barberà-Cremades M; Baroja-Mazo A; Gomez AI; Machado F; Di Virgilio F; Pelegrín P
FASEB J; 2012 Jul; 26(7):2951-62. PubMed ID: 22490780
[TBL] [Abstract][Full Text] [Related]
7. Structure-Activity Relationships and Therapeutic Potential of Purinergic P2X7 Receptor Antagonists.
El Idrissi IG; Podlewska S; Abate C; Bojarski AJ; Lacivita E; Leopoldo M
Curr Med Chem; 2024; 31(11):1361-1403. PubMed ID: 37013427
[TBL] [Abstract][Full Text] [Related]
8. MiR-187-3p mimic alleviates ischemia-reperfusion-induced pain hypersensitivity through inhibiting spinal P2X7R and subsequent mature IL-1β release in mice.
Li XQ; Yu Q; Zhang ZL; Sun XJ; Ma H
Brain Behav Immun; 2019 Jul; 79():91-101. PubMed ID: 31100367
[TBL] [Abstract][Full Text] [Related]
9. The P2X7 purinergic receptor: a potential therapeutic target for lung cancer.
Li Q; Zhu X; Song W; Peng X; Zhao R
J Cancer Res Clin Oncol; 2020 Nov; 146(11):2731-2741. PubMed ID: 32892231
[TBL] [Abstract][Full Text] [Related]
10. Purinergic P2X7 receptor antagonist ameliorates intestinal inflammation in postoperative ileus.
Kimura H; Yamazaki T; Mihara T; Kaji N; Kishi K; Hori M
J Vet Med Sci; 2022 Apr; 84(4):610-617. PubMed ID: 35249909
[TBL] [Abstract][Full Text] [Related]
11. Arylboronic acids inhibit P2X7 receptor function and the acute inflammatory response.
Faria RX; de Jesus Hiller N; Salles JP; Resende JALC; Diogo RT; von Ranke NL; Bello ML; Rodrigues CR; Castro HC; de Luna Martins D
J Bioenerg Biomembr; 2019 Aug; 51(4):277-290. PubMed ID: 31256283
[TBL] [Abstract][Full Text] [Related]
12. The role and pharmacological properties of the P2X7 receptor in neuropathic pain.
Zhang WJ; Zhu ZM; Liu ZX
Brain Res Bull; 2020 Feb; 155():19-28. PubMed ID: 31778766
[TBL] [Abstract][Full Text] [Related]
13. The P2X7 receptor: A main player in inflammation.
Adinolfi E; Giuliani AL; De Marchi E; Pegoraro A; Orioli E; Di Virgilio F
Biochem Pharmacol; 2018 May; 151():234-244. PubMed ID: 29288626
[TBL] [Abstract][Full Text] [Related]
14. Magnesium sulfate inhibits inflammation through P2X7 receptors in human umbilical vein endothelial cells.
Ozen M; Xie H; Shin N; Al Yousif G; Clemens J; McLane MW; Lei J; Burd I
Pediatr Res; 2020 Feb; 87(3):463-471. PubMed ID: 31493768
[TBL] [Abstract][Full Text] [Related]
15. Recent Advances in the Development of Antidepressants Targeting the Purinergic P2X7 Receptor.
Lee S; Ha H; Jang J; Byun Y
Curr Med Chem; 2023; 30(2):164-177. PubMed ID: 35770396
[TBL] [Abstract][Full Text] [Related]
16. Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432.
Lord B; Aluisio L; Shoblock JR; Neff RA; Varlinskaya EI; Ceusters M; Lovenberg TW; Carruthers N; Bonaventure P; Letavic MA; Deak T; Drinkenburg W; Bhattacharya A
J Pharmacol Exp Ther; 2014 Dec; 351(3):628-41. PubMed ID: 25271258
[TBL] [Abstract][Full Text] [Related]
17. Neuropsychopharmacology of JNJ-55308942: evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia.
Bhattacharya A; Lord B; Grigoleit JS; He Y; Fraser I; Campbell SN; Taylor N; Aluisio L; O'Connor JC; Papp M; Chrovian C; Carruthers N; Lovenberg TW; Letavic MA
Neuropsychopharmacology; 2018 Dec; 43(13):2586-2596. PubMed ID: 30026598
[TBL] [Abstract][Full Text] [Related]
18. The role of P2X7 purinergic receptors in inflammatory and nociceptive changes accompanying cyclophosphamide-induced haemorrhagic cystitis in mice.
Martins JP; Silva RB; Coutinho-Silva R; Takiya CM; Battastini AM; Morrone FB; Campos MM
Br J Pharmacol; 2012 Jan; 165(1):183-96. PubMed ID: 21675966
[TBL] [Abstract][Full Text] [Related]
19. The P2X7 Receptor: A Promising Pharmacological Target in Diabetic Retinopathy.
Tassetto M; Scialdone A; Solini A; Di Virgilio F
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281162
[TBL] [Abstract][Full Text] [Related]
20. A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signalling.
Hasan D; Shono A; van Kalken CK; van der Spek PJ; Krenning EP; Kotani T
Purinergic Signal; 2022 Mar; 18(1):13-59. PubMed ID: 34757513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
